Company profile
ENDRA Life Sciences Inc.
NASDAQ: NDRA · Healthcare · Medical - Diagnostics & Research
#1161 of 1,418 Healthcare companies by revenue
EA Score
25DFH 23DQ 23GM 31SS 38
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, growth stability · ↓ 3-yr revenue growth, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$7.0M
Employees
10
as of 2026-08-24
Market cap
$5.7M
as of 2026-08-24
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02020
Net income-$7.0M-$7.0M2025
Operating income-$5.8M-$5.8M2025
Total assets$3.9M$3.9M2025
Liabilities$1.6M$1.6M2025
Equity$2.3M$2.3M2025
Revenue trend
FY2017 – FY2020 · USD
FY17
FY18
FY18
FY19
FY20
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is ENDRA Life Sciences Inc.’s revenue?
ENDRA Life Sciences Inc. booked $0 in FY2020 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Sweet Earth Holdings Corporation22DProcessa Pharmaceuticals, Inc.39DPharmaCyte Biotech, Inc.——WEED, Inc.19DMustang Bio, Inc.41DStimcell Energetics, Inc.20DNeighbors
Washtenaw →Key facts
CEOAlexander Y. Tokman
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersAnn Arbor, MI
ExchangeNASDAQ: NDRA
Employees10
IPO date2017-06-30
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.